AHK-Cu — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

AHK-Cu

Also known as: L-alanyl-L-histidyl-L-lysine-Cu2+, tripeptide-copper complex, AHK copper complex

Copper-binding tripeptide / growth factor peptide

Research chemicalLast updated: November 4, 2026Based on 1 peer-reviewed studyPreclinical data only — no human trials

What it is

AHK-Cu is a copper-binding peptide people use for hair growth and scalp health. Limited research suggests it may stimulate hair follicle activity in lab settings. No FDA-approved use; evidence comes from one published study and is at an early stage.

The scientific side

Based on the single available abstract, AHK-Cu (L-alanyl-L-histidyl-L-lysine-Cu2+) is described as a growth factor for various kinds of differentiated cells. In the context of hair biology, AHK-Cu stimulated the elongation of human hair follicles ex vivo and the proliferation of dermal papilla cells (DPCs) in vitro. At 10⁻⁹ M, AHK-Cu elevated the Bcl-2/Bax ratio and reduced levels of cleaved caspase-3 and PARP, suggesting an anti-apoptotic effect in DPCs. The compound is also reported to stimulate dermal fibroblast proliferation, elevate vascular endothelial growth factor (VEGF) production, and decrease transforming growth factor-beta1 (TGF-β1) secretion by dermal fibroblasts. The proposed mechanism for hair growth promotion is stimulation of DPC proliferation and preclusion of DPC apoptosis.

Class: Copper-binding tripeptide / growth factor peptide

Administration & storage

Cautions
No human pharmacokinetic or safety data are available in the reviewed literature.,All dose data derive from in vitro / ex vivo experiments; translation to human dosing has not been established in the reviewed literature.,No formulation, purity, or sterility specifications for injectable or topical use are described in the available abstract.,Sterile technique should always be applied when handling any peptide preparation intended for administration — general best practice.

Legal & regulatory status

US FDA

Not stated in reviewed literature — requires manual verification

WADA

Not stated in reviewed literature — requires manual verification

Health Canada

Not stated in reviewed literature — requires manual verification